ArticleCurrent oncology (Toronto, Ont.)2023

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.

Balázs Jóri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.